Ignite Creation Date:
2024-05-06 @ 6:50 PM
Last Modification Date:
2024-10-26 @ 2:55 PM
Study NCT ID:
NCT05795595
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2023-03-21
Brief Title:
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Sponsor:
CRISPR Therapeutics AG
Organization:
CRISPR Therapeutics
Study Overview
Official Title:
A Phase 12 Open-label Multicenter Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter Phase 12 study evaluating the safety and efficacy of CTX131 in subjects with relapsed or refractory solid tumors
Detailed Description:
An open-label multi-center Phase 12 study of CTX131 in subjects with relapsedrefractory solid tumors CTX131 is an is allogeneic CD70- directed chimeric antigen receptor CAR T cell immunotherapy comprised of allogeneic T cells that are genetically modified ex vivo using CRISPR-Cas9 clustered regularly interspaced short palindromic repeats CRISPR associated protein 9 gene editing components single guide RNA and Cas9 nuclease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None